

BACKGROUND

How Sonic Incytes is Redefining the Standard of Care in Quantifying Chronic Liver Disease with Velacur™

Approximately 1 in 4 persons worldwide has fatty liver disease, the fastest growing and largest segment of chronic liver disease, driven largely by the increasing prevalence of diabetes and obesity. By 2030, there will be more than 150 million people in the United States alone that have or are at risk of fatty liver disease, with the majority underdiagnosed.

The liver, which is a critical organ for ridding the body of harmful substances, can be damaged with excess fat accumulation. This results in chronic inflammation, leading to scarring and eventually liver failure. The good news is that if detected early, fatty liver disease can be stopped from progressing and potentially reversed, protecting the health of your liver. Those who are obese and/or diabetic – or at risk for these conditions – would benefit greatly.

Definitive diagnostic tools for this disease are currently limited to biopsy and MRI, which are invasive, expensive, and inconvenient.

With Velacur™, there's now a practical way to assess millions of people before the onset of advanced disease. Velacur™ enables early diagnosis and improved management, preventing – and reversing – disease progression and the exponential rise in healthcare costs.

Sonic Incytes' breakthrough, portable, handheld ultrasound solution assesses and manages chronic liver disease with diagnostic accuracy that is comparable to MRI, the current non-invasive gold standard. Velacur™ is a point of care solution that provides consistently accurate results, and a clear picture of the liver, so physicians can be confident in the diagnosis, treatment and care of your health.

Our proprietary technology uses steady state waves, the same used by MRI elastography, to quantify liver disease, paving the way for a non-invasive, low-cost and scalable solution to assess and manage millions of patients. Velacur™'s attenuation measurement accurately quantifies liver fat content (steatosis) and its elasticity measurement stages tissue stiffness (fibrosis) in the liver.

Velacur™ consists of a handheld ultrasound and an activation pad. The patient lies on the activation pad, which creates steady state waves in the liver, and a 3D tissue sample is measured using the ultrasound probe. The entire procedure takes about five minutes in a doctor's office, providing for a quick, safe and comfortable patient experience. Liver health results are available immediately. Its portability allows physicians to integrate it in multiple practice settings.

In addition to fatty liver disease, Velacur™ can also be used to assess and manage other chronic liver diseases, resulting from viral infections, excessive alcohol consumption, and autoimmune or congenital conditions.

Founded in 2017, Sonic Incytes Medical Corp. is a medical technology company headquartered in Vancouver, Canada. Sonic Incytes plans to enter the market with its breakthrough, point of care ultrasound solution in early 2021, making Velacur™ the first handheld 3D liver tissue assessment tool with diagnostic accuracy comparable to MRI.

